Notice of contention
160 The Territory's notice of contention seeks to uphold the primary judge's decision on two grounds not relied on by his Honour. The first is:
'That the "product" said to be supplied, however described, was not a "product" the use of which would infringe the subject patent for the purposes of section 117 of the Act.'
161 In its written submissions the Territory contended that 'while the trees may contain the requisite bark and wood, the provision on the one hand of "Tree at Stump" and on the other of milled wood and stripped bark are sufficiently different so as to preclude the purported supply of the Trees from constituting a supply of the requisite "bark and wood"'.
162 The primary judge recorded the Territory's submission, but did not express an opinion on it.
163 As we understood the submission, it was directed to the opening part of s 117(1), and was in substance that what was used by ACOC was milled wood and stripped bark and what was supplied was trees, so that the product that was used was not the product that was supplied. What actually happened was that ACOC came onto the Territory's land and with its permission cut down the trees and took possession of the severed parts. Accordingly, what was supplied was felled trees or, for practical purposes, severed tree trunks. ACOC then stripped the bark from the timber and milled the remaining wood and subjected the bark and wood to its process in order to produce the oil. In the ordinary use of words ACOC used the tree trunks by stripping off the bark and milling the wood and using both in its process. That is plainly a use of the tree trunks. What was supplied and what was used are the same thing.
164 The second ground in the notice of contention is
'That the product that could be relevantly described as an input into the process in the subject patent was:
(i) the bark and wood of Callitris Intratropica; and/or
(ii) the bark and wood of one or more species of the genus Callitris;
whereas what was purportedly 'supplied' in the present case was Trees of the species Callitris Intratropica.'
In the Territory's written submissions it was said that the two contentions in its notice were considered at [23] and [24] of his Honour's reasons, but that he made no finding one way or the other. The paragraphs in question are in fact [22] and [23] of the reasons. Paragraph 23 deals with the first ground that we have rejected. At [22] his Honour said:
'If I were to accept the Territory's contention, it would follow that s 117(1) did not apply to the "supply" of the timber to ACOC by the Territory in any event, because ACOC's use of the product supplied (the timber) did not itself infringe the patent.'
165 The 'Territory's contention' was based on s 13(1) of the Patents Act:
'Subject to this Act, a patent gives the patentee the exclusive rights, during the term of the patent, to exploit the invention and to authorise another person to exploit the invention.'
The word 'exploit', in relation to an invention, includes:
'(a) where the invention is a product - make, hire, sell or otherwise dispose of the product, offer to make, sell, hire or otherwise dispose of it, use or import it, or keep it for the purpose of doing any of those things; or
(b) where the invention is a method or process - use the method or process or do any act mentioned in paragraph (a) in respect of a product resulting from such use.'
The argument was that where a patent is in respect of a method or process, the only means by which the use of a product could infringe is if the use constitutes the making, hiring, selling etc of a product resulting from the use of the patented process. It was said to follow from this that the word 'product' in s 117 could never apply to an input into a process.
166 This submission was founded on Rescare Ltd v Anaesthetic Supplies Pty Ltd (1992) 111 ALR 205. So far as relevant to the present case, Rescare concerned claim 9 of a patent over an invention entitled 'Device for treating snoring sickness'. The device provided a means of overcoming obstructive sleep apnoea, and involved treatment with continuous positive airway pressure applied via a nose mask. Most of the claims of the patent were apparatus claims. Claim 9, as notionally amended for presently immaterial reasons, was a method claim:
'A method of treating … obstructive sleep apnoea in a patient comprising: applying air through a nose piece at a pressure maintained slightly greater than atmospheric substantially continuously throughout the breathing cycle.'
The applicant patentee complained that the respondent had promoted, displayed and offered for sale at two hospitals apparatus for administering continuous positive airway pressure to treat obstructive sleep apnoea. It relied on s 117(2)(c). Gummow J said:
'the applicant urges … that there is a relevant use if the respondent's devices are used in accordance with any instructions for use or in accordance with any inducement to use them, in either case given by the supplier or contained in an advertisement published by or with the authority of the supplier. Therefore, it is submitted, the supply of the allegedly infringing devices by the respondent, with instructions for use, is itself an infringement of claim 9, a method claim, by the respondent as supplier.
The difficulty with that proposition is that a pre-condition to the operation of s 117 in relation to a method claim such as claim 9, is that there is a product the use of which by the respondent would infringe claim 9. In other words, that user would have to amount to an "exploitation" within the monopoly conferred by s 13, which is to be read with par (b) of the definition of "exploit".
As I have indicated, where the invention relevantly claims a method or process, exploitation occurs, other than by use of the method or process, only by the doing of an act mentioned in para (a) of the definition of "exploit". There must be an act done "in respect of a product resulting from such use". Here … there is no such product with the result that, in a case such as the present, s 117 has no operation.'
167 On appeal to the Full Court, Lockhart J, with whom Wilcox J agreed, upheld Gummow J's construction of s 117, namely that it is a precondition to the operation of the section in relation to a method claim that there be a product the use of which would infringe that method claim: Anaesthetic Supplies Pty Ltd v Rescare Ltd (1994) 50 FCR 1 at 24.
168 In Sartas No 1 Pty Ltd v Koukourou & Partners Pty Ltd (1994) 30 IPR 479 at 495 Gummow J repeated what he had said in Rescare.
169 Doubt was cast on the Rescare approach in Bristol‑Myers Squibb Co v FH Faulding & Co Ltd (2000) 97 FCR 524. The appellant was the proprietor of two petty patents for methods of administering taxol, a drug having anti‑carcinogenic properties. The claims of both patents involved a method of administering a certain dosage of taxol over a specified period of time. The respondent sold and supplied taxol to doctors and hospitals, together with a product information guide which included recommendations that the drug be used for the treatment of cancer, in the same dosage amounts and over the same period of time as specified in the patents. The primary judge upheld the respondent's cross claim for revocation on the grounds that the invention lacked novelty, the claims were not fairly based, and there was no inventive step. His Honour was of the view that had the patents been valid, they would not have been infringed. In rejecting the appellant's reliance on s 117 his Honour applied Rescare. The Full Court affirmed the decision as to revocation on the ground of lack of novelty. Black CJ and Lehane J nevertheless went on to consider infringement. At [84] their Honours said that the use of taxol in accordance with the method recommended in the respondent's guide would be an infringement by the doctors and hospitals. But did the respondent infringe? That depended on s 117.
170 After noting that the Full Court's observations in Rescare about s 117 were obiter, and that the approach adopted in that case resulted in s 117 having a very limited operation, if any, Black CJ and Lehane J continued at [95]:
'it is perhaps a pity that the drafter chose to use the phrase 'use of a product', which contains such a clear reference to the terminology of par (a) of the definition of "exploit". But s 117 provides its own dictionary, in subs (2). And our paraphrase of s 117(1), incorporating subs (2)(c), shows, in our view, that the construction urged by the appellant is not only a possible construction but a literal one. That literal construction being consistent with the apparent purpose of the provision, it is, in our view, plainly to be preferred.'
171 The 'paraphrase' referred to, which appears at [87] of Bristol‑Myers, is in fact the appellant's (the patentee's):
'If the use of [taxol] by a [medical practitioner], in accordance with any instructions for the use of taxol ... given to the [medical practitioner] by the [respondent] ..., would infringe [either of the petty patents], the supply of that [taxol] by [the respondent] to [the medical practitioner] is an infringement of the [petty patent] by the [the respondent] ….'
172 Put shortly, the joint judgment in Bristol‑Myers involves putting aside the definition of 'exploit' and resorting instead to the uses referred to in s 117(2). For the purposes of the present case a paraphrase of s 117(1), incorporating sub‑s (2)(b), would read:
'If:
(a) ACOC's use of the product would infringe the patent, and
(b) the Territory, as supplier of the product to ACOC, had reason to believe that ACOC would so use the product,
then, the supply of the product is an infringement of the patent by the Territory.'
173 If the product used in (a) and supplied in (b) is the same thing, namely the timber, infringement by the Territory is established (assuming the Territory had reason to believe). If, as contended by the Territory, it was not the timber that was used by ACOC but the selected bark and wood from the timber, then assuming the timber and its bark and wood are different products, infringement by the Territory will not be established. ACOC will not have used the product that the Territory supplied to it. As appears from [163], we have concluded that the product used and that supplied are the same thing.
174 Because the primary judge decided the separate question against the appellants on 'supply' and 'staple commercial product', he did not need to choose between Rescare and Bristol‑Myers. His Honour did at [22] of his reasons say that, had there been no other obstacle in the appellants' way, and if he were to apply Rescare, he would have held that s 117(1) did not apply to the Territory's assumed supply of timber, because ACOC's use of the timber did not infringe the patent. But his Honour did not say what, on the same assumptions, he would have held had he decided to adopt what had been said in Bristol‑Myers. He simply recorded at [23] the Territory's contention that it was the trees or timber that was supplied to ACOC, but the product used by ACOC was not the trees or the timber but the selected bark and wood from the timber.
175 It is not necessary for us to express a preference in relation to the approaches adopted in Rescare and Bristol‑Myers. That is because the submission based on Rescare is directed to whether ACOC has infringed the patent. That enquiry is outside the scope of the separate questions. We will explain why.
176 The appellants' statement of claim alleges that ACOC used the timber acquired from the Territory to produce a blue coloured oil by means of a process protected by the patent, and has sold and offered it for sale within Australia. The Territory does not admit the allegation. It also puts in issue the validity of the patent.
177 The first of the issues in the separate question is whether the Territory had supplied a product to ACOC its use of which would infringe the patent. The ambit of the question was squarely raised at the beginning of argument before the primary judge. Counsel for the Territory said:
'And it's those last words, "the use of which would infringe the patent", which I wish to raise now, because plainly … the determination of that part of the question would involve questions of ultimate or primary infringement by ACOC and we would simply wish to clarify that that would not be a matter that your Honour could determine today, there being no evidence of end use by ACOC in any event.'
HIS HONOUR: So the emphasis is on the question of supply?
MS GODDARD: The question, we say, is on the question of supply, on the question of what is the product supplied and whether or not that product is a staple commercial product ….
…
And its those ultimate questions which we wish to make pellucidly clear, including the question of end use or primary infringement by ACOC that are not in issue today.
HIS HONOUR: Yes. All right ….'
178 In his reasons, immediately after setting out the separate questions, the primary judge said:
'That order was made to address the alleged contributory infringement of the patent by the Territory without extending the hearing into issues as to the validity of the patent, and its infringement by ACOC. As I have said, for present purposes I have assumed the validity of the patent, and that ACOC's alleged actions have infringed it.'